Complement inhibition at the level of C3 or C5: Mechanistic reasons for ongoing terminal pathway activity
- Marco Mannes
- , Arthur Dopler
- , Oliver Zolk
- , Sophia J. Lang
- , Rebecca Halbgebauer
- , Britta Höchsmann
- , Arne Skerra
- , Christian K. Braun
- , Markus Huber-Lang
- , Hubert Schrezenmeier
- , Christoph Q. Schmidt
- University of Ulm
- University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
- Institute for Clinical Transfusion Medicine and Immunogenetics Ulm
Research output: Contribution to journal › Article › peer-review
94
Scopus
citations